This article was downloaded by: [University Of Pittsburgh] On: 11 July 2014, At: 02:31 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lsyc20</u>

A Preferred Synthesis of 1,2,4-Oxadiazoles

Brenda Pipik^a, Guo-Jie Ho^a, J. Michael Williams^a & David A. Conlon^a

^a Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey, 07065, USA Published online: 20 Aug 2006.

To cite this article: Brenda Pipik , Guo-Jie Ho , J. Michael Williams & David A. Conlon (2004) A Preferred Synthesis of 1,2,4-Oxadiazoles, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 34:10, 1863-1870, DOI: <u>10.1081/SCC-120034169</u>

To link to this article: http://dx.doi.org/10.1081/SCC-120034169

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

SYNTHETIC COMMUNICATIONS[®] Vol. 34, No. 10, pp. 1863–1870, 2004

A Preferred Synthesis of 1,2,4-Oxadiazoles

Brenda Pipik,^{*} Guo-Jie Ho, J. Michael Williams, and David A. Conlon

Department of Process Research, Merck Research Laboratories, Rahway, New Jersey, USA

ABSTRACT

An efficient and high-yielding one-pot synthesis of 1,2,4-oxadiazoles from carboxylic acids and amidoximes is described. Activation of the carboxylic acid using hydroxybenzotriazole (HOBt) and EDC/HCl followed by reaction with an amidoxime generates an oxime ester. Without isolation, the oxime ester is dehydrated to give the oxadiazole ring.

Key Words: 1,2,4-Oxadiazoles; Carboxylic acids; Hydroxybenzotriazole; High-yielding synthesis.

INTRODUCTION

Substituted 1,2,4-oxadiazoles are important pharmacophores found in pharmaceutical candidates, which are often used to replace ester or amide

```
1863
```

DOI: 10.1081/SCC-120034169 Copyright © 2004 by Marcel Dekker, Inc. 0039-7911 (Print); 1532-2432 (Online) www.dekker.com

^{*}Correspondence: Brenda Pipik, Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA; E-mail: brenda_pipik@ merck.com.

functions. Starting from acid (**I**), an efficient and high-yielding synthesis of 3-methyl-5-[4-(methylsulfonyl)benzyl]-1,2,4-oxadiazole^[1] suitable for large-scale production was required (Sch. 1). Several different approaches starting from the carboxylic acid and using a variety of peptide coupling reagents were explored. These methods included carbonyl activation using CDI,^[2] DCC,^[3] formation of an acid chloride,^[4] or anhydride.^[5] None of these approaches were applicable to large-scale synthesis, because, most were low yielding or required isolation by chromatography to afford product with acceptable purity. An optimized procedure was developed which involved activation of 4-(methylsulfonyl)phenylacetic acid using standard peptide coupling reagents EDC/HCl and hydroxybenzotriazole (HOBt)^[6] followed by displacement with methylamidoxime.^[7] Cyclization and dehydration took place upon heating, without the addition of other reagents. Compound **3** was produced on a 30 kg scale in 90% yield employing this method.

1864

We report herein the results from our studies on the application of this procedure using these peptide-coupling reagents to form a wide range of oxadiazoles. A series of carboxylic acids (Table 1) was successfully activated using a combination of HOBt and EDC/HCl. Displacement of HOBt from the ester intermediate by methylamidoxime or commercially available 4-fluorobenzamidoxime occurred readily at room temperature in acetonitrile. It was critical to ensure that the active ester formation was complete before addition of the amidoxime. Low conversion of the starting carboxylic acid was observed when all the reagents were charged at once, possibly due to the reaction of the amidoxime with EDC/HCl. Other peptide coupling reagents such as 2-isobutoxy-1-isobutoxycarbonyl-1,2-dihydroquinoline (IIDQ) and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) were not effective even when used in excess (greater than 2 equiv.), and generated impurities due to side reactions.

The Z-isomer of the O-acylated intermediate II was isolated for structural confirmation by NMR, and was found to be consistent with previously reported structures.^[3,4] Cyclodehydration of II to form the oxadiazole occurred on heating. In some cases, water removal was necessary to avoid the competing hydrolysis of the oxime ester which regenerates the starting carboxylic acid. On laboratory scale, water removal was accomplished by heating to reflux and returning the condensate through a bed of molecular sieves which were contained in an addition funnel.^a Aromatic compounds containing an electron donating group para to the carboxylic acid were more sensitive to hydrolysis compared to those containing an electron withdrawing group such as cyano. The compounds containing an electron donating group

Marcel Dekker, Inc

270 Madison Avenue, New York, New York 10016

^aA Soxhlet apparatus was not as efficient in water removal.

Synthesis of 1,2,4-Oxadiazoles







ORDER		REPRINTS
-------	--	----------

Entry	Oxadiazole	Method ^a	Isolated yield (%)	Lit. yield (%)
1	MeO-	А	70	68, ^[8] 53 ^[2]
2		В	88	60 ^[2]
3		А	90	_
4		В	76	—
5		В	70	_
6		В	69	_
7	MeO	А	60	51 ^[2]
8		В	93	63 ^[2]
9	MeO ₂ S	А	78	_
	\ F			

Table 1. Yields of 1,2,4-oxadiazoles.

1866



Synthesis of 1,2,4-Oxadiazoles

1867

Entry	Oxadiazole	Method ^a	Isolated yield (%)	Lit. yield (%)
10		В	93	_
11		В	76	—
12		В	73	—
	CBZ ^N H			

Table 1. Continued.

^a*Method A:* In acetonitrile, the mixture was heated to reflux and the condensate dried over a bed of sieves. *Method B:* Reaction mixture was solvent switched from acetonitrile to diethoxyethane after formation of the oxime ester.

also required a longer reaction time for cyclization, thus, making the uncyclized intermediate available for hydrolysis in the presence of water generated during cyclization. In such cases, we found that switching the solvent from acetonitrile to a higher boiling solvent such as diethoxyethane or toluene compensated for this rate decrease. The poor solubility of EDC/HCl in diethoxyethane and toluene precluded the use of these solvents in the initial stage of the reaction, because, a gummy material formed in the mixture so that reaction in these solvents was not conducive to scale-up. Therefore, the formation of the oxime ester was carried out in acetonitrile and then the reaction solvent was switched to toluene or diethoxyethane. For those substrates containing an electron withdrawing group, the entire reaction sequence was carried out in acetonitrile and the cyclization went to completion cleanly and in high yield (Table 1).

Excellent stereochemical retention was also demonstrated starting from an amino acid with this method. When the oxadiazole was formed from CBZ-L-serine and methylamidoxime, the product was obtained in >95% ee. In the case of CBZ-L-serine and 4-fluorobenzamidoxime, there was complete retention of stereochemistry.

In conclusion, this communication describes an optimized, high-yielding synthesis of 1,2,4-oxadiazoles. The process is easily scalable, as was demonstrated on 30 kg and is suitable for use in preparation of a wide variety of substrates.

	RINTS
--	-------

EXPERIMENTAL

1868

Overall yields were determined by evaporation to dryness and were corrected based on quantitative assay by HPLC against a standard of known purity. Yields were reproducible and structures were confirmed by ¹H and ¹³C NMR spectroscopy, HPLC and elemental analysis. NMR spectra were recorded on a Bruker DPX 400.

Typical Procedures

Method A: A carboxylic acid (20 mmol) and HOBt (24 mmol) are slurried in dry acetonitrile (50 mL). Addition of EDC/HCl (23 mmol) to this mixture at room temperature generates the HOBt ester. Methylamidoxime or 4-fluorobenzamidoxime is added and the mixture is heated to reflux. The condensate is returned through a bed of molecular sieves, which are contained in an addition funnel. After concentration of the reaction mixture, the oxadiazole is isolated by partitioning with ethyl acetate and aqueous bicarbonate solution. Concentration of the separated organics is followed by crystallization of the oxadiazole from isopropanol or isopropanol/hexane.

Method B: Ester formation as above. In cases where hydrolysis of the HOBt ester occurs readily, the reaction mixture solvent is switched at this point from acetonitrile to a higher boiling solvent such as diethoxyethane and the resulting solution is heated to reflux. When using this procedure, the reaction goes to completion in 4-6 hr without the use of sieves to remove water. The reaction workup is the same as above.

3-Methyl-5-[4-(methylsulfonyl)benzyl]-1,2,4-oxadiazole (3). ¹H-NMR (CDCl₃) δ 7.90 (m, 2H), 7.52 (m, 2H), 4.27 (s, 2H), 3.02 (s, 3H), 2.35 (s, 3H); ¹³C-NMR (CDCl₃) δ 176.3, 167.4, 139.9, 139.6, 129.9, 127.9, 44.4, 32.6, 11.4. Analytical Calculated: C, 52.37; H, 4.79; N, 11.10. Found: C, 52.34; H, 4.69; N, 11.00; mp 90–91°C (dec).

Benzyl[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]carbamate (4). ¹H-NMR (CDCl₃) δ 7.31 (m, 5H), 5.56 (d, J = 6.4, 1H), 5.13 (m, 3H), 2.37 (s, 3H), 1.57 (d, J = 7.2, 3H); ¹³C-NMR (CDCl₃) δ 179.5, 167.2, 155.5, 136.1, 128.6, 128.3, 128.2, 67.3, 44.6, 19.9, 11.5. Analytical Calculated: C, 59.76; H, 5.79; N, 16.08. Found: C, 59.64; H, 5.83; N, 16.25.

Benzyl[2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]carbamate (5). ¹H-NMR (CDCl₃) δ 7.36 (m, 5H), 5.47 (d, J = 9.2, 1H), 5.15, 5.11 (AB quartet, J = 12.2, 2H), 4.97 (dd, J = 9.2, J = 5.9, 1H), 2.39 (s, 3H), 2.25 (m, 1H), 0.96 (d, J = 7.2, 6H); ¹³C-NMR (CDCl₃) δ 178.4, 167.0, 155.9, 136.0, 128.5, 128.3, 128.2, 67.3, 54.0, 32.5, 18.6, 17.8, 11.5. Analytical Calculated: C, 62.27; H, 6.62; N, 14.52. Found: C, 62.57; H, 6.63; N, 14.35; mp.



Copyright @ Marcel Dekker, Inc. All rights reserved

	REPRINTS
--	----------

Synthesis of 1,2,4-Oxadiazoles

Benzyl[2-hydroxy-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]carbamate (6). ¹H-NMR (CDCl₃) δ 7.34 (m, 5H), 6.05 (d, J = 8.6, 1H), 5.12 (m, 3H), 4.06 (dd, J = 11.3, 3.1, 1H), 3.95 (dd, J = 11.3, 4.0, 1H), 2.97 (br s, 1H), 2.36 (s, 3H); ¹³C-NMR (CDCl₃) δ 177.1, 167.1, 156.0, 135.8, 128.6, 128.3, 128.2, 67.5, 63.2, 50.5, 11.4. Analytical Calculated: C, 56.31; H, 5.45; N, 15.15. Found: C, 56.44; H, 5.33; N, 15.05; mp 116–117°C (dec).

3-(4-Fluorophenyl)-5-[4-(methylsulfonyl)benzyl]-1,2,4-oxadiazole (9). ¹H-NMR (CDCl₃) δ 8.08 (m, 2H), 7.97 (m, 2H), 7.45 (m, 2H), 7.18 (m, 2H), 4.40 (s, 2H), 3.06 (s, 3H); ¹³C-NMR (CDCl₃) δ 176.8, 167.8, 164.6 (d, J = 251.7), 140.1, 139.6, 130.1, 129.6 (d, J = 8.8), 128.1, 122.7 (d, J = 3.1), 116.1 (d, J = 22.0), 44.5, 32.8. Analytical Calculated: C, 57.82; H, 3.94; N, 8.43. Found: C, 57.87, H, 3.80, N, 8.46; mp 129–130°C (dec).

Benzyl{1-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]ethyl}carbamate (10). ¹H-NMR (CDCl₃) δ 8.07 (m, 5H), 7.38 (m, 2H), 7.17 (m, 2H), 5.51 (d, J = 7.4, 1H), 5.24 (m, 1H), 5.17, 5.15 (AB quartet, J = 12.5, 2H), 1.66 (d, J = 7.2, 3H); ¹³C-NMR (CDCl₃) δ 179.8, 167.6, 164.7 (d, J = 251.8), 155.5, 136.0, 129.8 (d, J = 8.8), 128.7, 128.4, 128.3, 122.8 (d, J = 3.2), 116.1 (d, J = 21.7), 67.4, 44.8, 20.1. Analytical Calculated: C, 63.34; H, 4.72; N, 12.31. Found: C, 63.30; H, 4.58; N, 12.30; mp 110–111°C (dec).

Benzyl{1-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl} carbamate (11). ¹H-NMR (CDCl₃) δ 8.08 (m, 2H), 7.38 (m, 5H), 7.17 (m, 2H), 5.47 (d, J = 8.9, 1H), 5.17, 5.15 (AB quartet, J = 12.5, 2H), 5.07 (dd, J = 8.9, 5.85, 1H), 2.32 (m, 1H), 1.01 (d, J = 6.8, 6H); ¹³C-NMR (CDCl₃) δ 178.8, 167.4, 164.7 (d, J = 251.8), 156.0, 136.1, 129.8 (d, J = 8.7), 128.7, 128.4, 128.3, 122.9 (d, J = 3.2), 116.1 (d, J = 22.0), 67.5, 54.3, 32.7, 18.7, 17.9. Analytical Calculated: C, 65.03; H, 5.46; N, 11.38. Found: C, 64.90; H, 5.19; N, 11.29; mp 82–84°C (dec).

Benzyl{1-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-hydroxyethyl} carbamate (12). ¹H-NMR (CDCl₃) δ 8.04 (m, 2H), 7.36 (m, 5H), 7.15 (m, 2H), 6.0 (d, J = 8.8, 1H), 5.23 (m, 1H), 5.16 (s, 2H), 4.17 (dd, J = 11.2, 2.8, 1H), 4.05 (dd, J = 11.2, 3.6, 1H), 2.59 (br s, 1H); ¹³C-NMR (CDCl₃) δ 177.4, 167.5, 164.7 (d, J = 252.2), 155.9, 135.8, 129.7 (d, J = 8.8), 128.6, 128.4, 128.2, 122.4 (d, J = 3.2), 116.1 (d, J = 22.3), 67.6, 63.4, 50.6. Analytical Calculated: C, 60.50; H, 4.51; N, 11.76. Found: C, 60.55; H, 4.31; N, 11.77; mp 104–105°C (dec).

ACKNOWLEDGMENTS

We thank Dr. Raymond Cvetovich and Dr. E.J.J. Grabowski for helpful discussions. Thanks to Lisa DiMichele and Bob Reamer for NMR

Marcel Dekker, Inc.

270 Madison Avenue, New York, New York 10016

1869

ORDER		REPRINTS
-------	--	----------

confirmations and Mirlinda Biba for SFC chiral separations for the oxadiazoles prepared from serine.

REFERENCES

- Deschenes, D.; Dube, D.; Gallant, M.; Girard, Y.; Lacombe, P.; Macdonald, D.; Mastracchio, A.; Perrier, H. Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors. International Patent WO2002060897, June 28, 2001.
- Deegan, T.L.; Nitz, T.J.; Cebzanov, D.; Pufko, D.E.; Porco, J.A. Bioorg. Med. Chem. Lett. 1999, 9, 209–212.
- 3. Liang, G.-B.; Feng, D.D. Tetrahedron Lett. 1996, 37, 6627-6630.
- Diana, G.D.; Volkots, D.L.; Hitz, T.J.; Bailey, T.R.; Long, M.A.; Vescio, N.; Aldous, S.; Pevear, D.C.; Dutko, F.J. J. Med. Chem. 1994, 37, 2421–2436.
- Borg, S.; Estenne-Bouhtou, G.; Luthman, K.; Csoregh, I.; Hesselink, W.; Hacksell, U. J. Org. Chem. 1995, 60, 3112–3120.
- (a) Rudolph, J.; Theis, H.; Hanke, R.; Endermann, R.; Johannsen, L.; Geschke, F.-U. J. Med. Chem. 2001, 44, 619–626; (b) Nozaki, S. Chem. Lett. 1997, 1–2.
- 7. Eloy, F.; Lenaers, R. Chem. Rev. 1961, 62, 155-183.
- 8. Young, J.R.; DeVita, R.J. Tetrahedron Lett. 1998, 39, 3931-3934.

Received in the USA January 6, 2004



1870

Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/ Order Reprints" link below and follow the instructions. Visit the <u>U.S. Copyright Office</u> for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on <u>Fair Use in the Classroom</u>.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our <u>Website</u> User Agreement for more details.

Request Permission/Order Reprints

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081SCC120034169